Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy

[1]  Sean A. Dilliard,et al.  Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs , 2023, Nature Reviews Materials.

[2]  Y. Zhang,et al.  HSP70-Promoter-Driven CRISPR/Cas9 System Activated by Reactive Oxygen Species for Multifaceted Anticancer Immune Response and Potentiated Immunotherapy. , 2022, ACS nano.

[3]  J. Conde,et al.  Nanodelivery of nucleic acids , 2022, Nature Reviews Methods Primers.

[4]  R. Zappasodi,et al.  A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance , 2022, Nature Immunology.

[5]  M. Hung,et al.  Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics , 2022, Nature Reviews Clinical Oncology.

[6]  B. Leavitt,et al.  The current landscape of nucleic acid therapeutics , 2021, Nature Nanotechnology.

[7]  Zhijun Sun,et al.  Turning cold tumors into hot tumors by improving T-cell infiltration , 2021, Theranostics.

[8]  A. Luster,et al.  Chemokines and the immune response to cancer. , 2021, Immunity.

[9]  Jin-Zhi Du,et al.  Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy , 2021, Nature Communications.

[10]  B. Manshian,et al.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors , 2021, Chemical reviews.

[11]  M. Ibáñez-Hernández,et al.  Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters , 2020, Frontiers in Oncology.

[12]  P. Wittkopp,et al.  Molecular and evolutionary processes generating variation in gene expression , 2020, Nature Reviews Genetics.

[13]  C. Gersbach,et al.  The once and future gene therapy , 2020, Nature Communications.

[14]  Xiao Han,et al.  Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics. , 2020, Accounts of chemical research.

[15]  G. Giaccone,et al.  Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. , 2020, The New England journal of medicine.

[16]  V. Boussiotis,et al.  Revisiting the PD-1 pathway , 2020, Science Advances.

[17]  C. Robert.  A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.

[18]  Seungpyo Hong,et al.  An Avidity-based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy. , 2020, Nano letters.

[19]  Yu Chen,et al.  Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice , 2020, Frontiers in Immunology.

[20]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[21]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[22]  Qiang Cheng,et al.  Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR/Cas gene editing , 2020, Nature Nanotechnology.

[23]  L. Kennedy,et al.  A review of cancer immunotherapy toxicity , 2020, CA: a cancer journal for clinicians.

[24]  P. Hegde,et al.  Top 10 Challenges in Cancer Immunotherapy. , 2020, Immunity.

[25]  G. Coukos,et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.

[26]  M. Edelman,et al.  Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors , 2019, Advances in Therapy.

[27]  S. Xiong,et al.  A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model , 2019, Cellular & Molecular Immunology.

[28]  S. O'Reilly,et al.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.

[29]  J. Wolchok,et al.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Azlan Abdul Aziz,et al.  Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles , 2018, Nanoscale Research Letters.

[31]  Ronald Boellaard,et al.  89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer , 2018, Nature Medicine.

[32]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[33]  Quanyin Hu,et al.  Delivery Strategies for Immune Checkpoint Blockade , 2018, Advanced healthcare materials.

[34]  V. Seshan,et al.  Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo , 2018, Nature Biotechnology.

[35]  Zhuang Liu,et al.  In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy , 2018, Science Translational Medicine.

[36]  Hideo Baba,et al.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.

[37]  J. Taube,et al.  PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression , 2018, The Journal of clinical investigation.

[38]  Michel Sadelain,et al.  Gene therapy comes of age , 2018, Science.

[39]  Zhen Gu,et al.  Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles. , 2018, ACS nano.

[40]  A. Chinnaiyan,et al.  Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. , 2018, The Journal of clinical investigation.

[41]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[42]  I. Frazer,et al.  Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity , 2017, Cell Death & Disease.

[43]  Weiping Zou,et al.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.

[44]  D. Hanahan,et al.  Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation , 2017, Science Translational Medicine.

[45]  Ian D. McGilvray,et al.  Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[46]  Ralph R. Weichselbaum,et al.  Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy , 2016, Nature Communications.

[47]  P. Cullis,et al.  Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[48]  Laura M Ensign,et al.  PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. , 2016, Advanced drug delivery reviews.

[49]  Zhen Gu,et al.  Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. , 2016, Nano letters.

[50]  Frederic Bartumeus,et al.  T cell migration, search strategies and mechanisms , 2016, Nature Reviews Immunology.

[51]  Xiaoxiao Wang,et al.  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. , 2016, Cancer cell.

[52]  James C. Whisstock,et al.  Perforin and granzymes: function, dysfunction and human pathology , 2015, Nature Reviews Immunology.

[53]  D. Pardoll,et al.  STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade , 2015, Science Translational Medicine.

[54]  Xiao-ling Lu,et al.  A novel recombinant protein of IP10-EGFRvIIIscFv and CD8+ cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice , 2013, Cancer Immunology, Immunotherapy.

[55]  M. Duffy,et al.  Survivin: a new target for anti-cancer therapy. , 2009, Cancer treatment reviews.

[56]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[57]  L. Tian,et al.  Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma , 2006, Gene Therapy.

[58]  A. Schacht,et al.  Direct Evidence that Toll-like Receptor 9 (TLR9) Functionally Binds Plasmid DNA by Specific Cytosine-phosphate-guanine Motif Recognition* , 2004, Journal of Biological Chemistry.

[59]  B. Liu,et al.  Transcriptional targeting of tumors with a novel tumor-specific survivin promoter , 2004, Cancer Gene Therapy.

[60]  M. Sadelain.  Insertional oncogenesis in gene therapy: how much of a risk? , 2004, Gene Therapy.

[61]  A. Feldman,et al.  Retroviral gene transfer of interferon‐inducible protein 10 inhibits growth of human melanoma xenografts , 2002, International journal of cancer.

[62]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[63]  M. Klüppel,et al.  The mouse tyrosinase promoter is sufficient for expression in melanocytes and in the pigmented epithelium of the retina. , 1991, Proceedings of the National Academy of Sciences of the United States of America.